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Neuroblastoma, a tumour arising from embryonal neuronal tissue,
accounts for 10% of all cancers in those under 15 years old with an
annual incidence of 6–8 per million. In the past it was always fatal
for children with metastatic disease over 12 months old. Now a
better understanding of the disease, with more sophisticated inves-
tigations and new therapies, has improved the 2-year survival rate
of children with advanced disease to 25%.
Accurate stratification of patients at diagnosis into different
prognostic groups is possible using various univariate methods
which relate clinical and biological factors to outcome (Evans
et al, 1987; Oppedal et al, 1988). Age at diagnosis is often con-
sidered to be the most important independent clinical prognostic
factor. In 1984, Shimada et al described age-dependent
histological criteria which have unequivocal bearing on prognosis.
Poor prognosis has been found to be associated with a number
of biochemical markers. However, chromosomal changes in
neuroblastoma are probably the most powerful biological factors
associated with prognosis in this disease. The most significant are
MYCN amplification, deletions at 1p36 and aneuploidy.
The  MYCN oncogene was first identified in 1983 and later
localized to 2p23–24 (Schwab et al, 1983, 1984). Amplified
MYCN is frequently in the form of homogeneously staining
regions found at varying chromosomal loci, but not at 2p23–24.
Amplification is present in 38% of stage 3 and 4 tumours (Brodeur
et al, 1984) and only 5–10% of patients with stage 1,2 or 4S
disease. (Brodeur and Fong, 1989). In many patient cohorts MYCN
amplification has been found to be associated with rapid tumour
progression and a poor outcome irrespective of the stage of the
tumour (Seeger et al, 1985; Tsuda et al, 1987; Taylor and Locker,
1990; Bourhis et al, 1991b; Look et al, 1991). Thus, in those with
early-stage tumours, which generally have a good prognosis,
MYCN amplification is an indicator of aggressive disease. Stage
4S, which is characterized by frequent spontaneous regression
without therapy, rarely shows amplification (Ambros et al, 1995).
Therapy is currently being directed according to MYCN gene
amplification. In infants with neuroblastoma and patients with
localized disease this guides their treatment.
Deletion of chromosome 1p is an independent indicator of poor
prognosis (Christiansen and Lampert, 1988; Hayashi et al, 1989)
and may be the most discriminant prognostic factor (Caron et al,
1996; Rubie et al, 1997). Early studies showing deletion in 70% of
samples concentrated on advanced tumours and cell lines (Brodeur
and Fong, 1989; Weith et al, 1989), which were likely to be a non-
representative group of aggressive, progressive tumours. Del(1p)
is less often found in stage 1 and 2 tumours (Hayashi et al, 1989;
Ambros et al, 1995). Assessments of loss of heterozygosity (LOH)
on chromosome 1p using polymorphic DNA markers, restriction
fragment length polymorphism (RFLP), polymerase chain reac-
tion (PCR) and single-strand conformation polymorphism (SSCP),
have produced estimates ranging from 10 to 37% (Fong et al,
1989; Peter et al, 1992; Caron et al, 1993, White et al, 1993;
Schleiermacher et al, 1994; Takeda et al, 1994; Rubie et al, 1997).
DNA ploidy is a major prognostic factor in neuroblastoma. In
1984, Look et al found that aneuploid tumours responded well to
chemotherapy. Flow cytometric studies correlated ploidy with
histological prognostic factors and clinical outcome, and
confirmed this (Gansler et al, 1986; Taylor et al, 1988). Absence of
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aneuploidy (a near diploid or near tetraploid DNA content), is
associated with more aggressive disease. Aneuploid, or near
triploid, karyotypes are extremely unlikely to have MYCN amplifi-
cation, whereas a subset of those without aneuploidy do have
MYCN amplification (Taylor and Locker, 1990; Bourhis et al,
1991a, 1991b). Look et al concluded that in children under 2 years
old tumour cell ploidy and MYCN copy number provide comple-
mentary prognostic information on which future treatment strate-
gies may be based (Look et al, 1984, 1991). 
Fluorescence in situ hybridization (FISH) and comparative
genomic hybridization (CGH) studies have recently established
that gain of chromosome 17 material is the most frequent abnor-
mality in neuroblastoma cells (Meddeb et al, 1996; Lastowska et al,
1997; Bown et al, 1999). Unbalanced gain of the long arm of chro-
mosome 17 is associated with other characteristics of poor prog-
nostic significance (age under 1 year, 1p loss, MYCN amplification
and adverse ploidy levels). The molecular pathology underlying
17q gain remains to be elucidated, but recent studies suggest that it
is a feature of considerable prognostic significance (Bown 
et al, 1998).
Standard techniques are effective for detection of prognostic
chromosome changes in neuroblastoma but may be impractical
owing to the time taken to perform the test, the quantity of tissue
required and other confounding factors. Southern blotting requires
more tumour tissue than FISH and results may be adversely
affected by admixture of normal tissue in the sample (Shapiro
et al, 1993). Karyotyping produces a high rate of del(1p) because
the abnormality itself confers a growth advantage in culture
(Christiansen et al, 1992).
In this study we employed interphase cytogenetic techniques
using FISH on tumour imprints from fresh biopsy material. We
previously evaluated this technique on control fibroblasts and
neuroblastoma cell lines as well as six primary tumour samples
(Taylor et al, 1994). We have now studied 58 patients samples
using probes for MYCN, 1p36 and centromere probes for ploidy.
We have applied these rapid simple techniques which circum-
vent the difficulties of culturing and karyotyping, and of molecular
techniques, allowing the results to be available to clinicians within
a few days of receipt of a fresh tissue biopsy.
MATERIALS AND METHODS
Materials
The plasmid probe for MYCN, pNb-9, consists of a genomic
HindIII fragment of 15 kb in pBR322. The chromosome 1
centromere probe used was pUC1.77, a satellite III repetitive DNA
probe located in the heterochromatic region of chromosome 1
(1q12) (Cooke and Hindley, 1979). CT4-1 is a 47-kb cosmid clone
which was isolated from a library using a plasmid subcloned DNA
probe p1–24, which maps close to the consensus deletion at
1p36.1–2 (Weith et al, 1989). A centromere probe p4.4 for
chromosome 8 was used as a control and to obtain additional
information about ploidy.
Human foreskin fibroblasts (HFF) were used throughout as a
normal control and neuroblastoma cell lines PCF, IMR32, Kelly,
GOTO, SK-N-BE, were used as controls for MYCN amplification.
Neuroblastoma samples were obtained via the UK Children’s
Cancer Study Group (UKCCSG) and the European
Neuroblastoma Study Group (ENSG). Fresh tumour biopsies were
initially sent in culture medium (RPMI-1640) by courier as soon
after removal from the patient as possible. Later tumour imprints
on glass slides, made by the histopathology staff at the hospital of
origin were sent dried but unfixed by ordinary mail. Other samples
received included bone marrow smears, cytospins and a fine
needle aspirate.
Methods
DNA probes
Plasmid and cosmid DNA preparation was carried out according
to standard mini-prep and maxi-prep techniques. The DNA used to
screen cosmid libraries was prepared from plasmid p1–24. Ten-
millilitre cultures were grown overnight with ampicillin and DNA
was isolated using the mini-prep procedure.
Cell culture and harvesting
HFFs were cultured in Dulbecco’s minimal essential medium
(DMEM) at 37°C supplemented with 10% fetal calf serum (FCS)
and 1% glutamine with 10% carbon dioxide (CO2). The neuroblas-
toma cell lines were cultured in DMEM with 10% FCS and 1%
non-essential amino acid supplement at 37°C with 10% CO2.
Direct nuclear preparations were prepared from fresh biopsy
samples of both types of tumour by mincing with scissors to
produce a single cell suspension as previously described (Taylor
et al, 1994).
Slide preparation
Imprints were made directly onto clean, non-coated slides using a
dry, blood-free, newly cut surface of fresh, unfixed biopsy mate-
rial. This was done as soon as possible after removal from the
patient, either at the hospital of origin, or after transport in tissue
culture medium (RPMI-1640) to the laboratory. Six imprints were
made of each specimen. Dry slides were then fixed and cleaned of
debris using glacial acetic acid (Taylor et al, 1994).
Glass microscope slides were wiped clean with fixative before
use with cultured cells and direct nuclear preparations. The cell
suspension was dropped onto the slide from a pipette and left to
dry. The density of the cells on the slides was checked using phase
microscopy and adjustments made by the addition or removal of
fixative.
Cytospin preparations were made at the hospital of origin directly
onto clean glass slides. Fluid obtained by fine-needle aspiration was
spread directly on clean slides at the referring hospital, and left to
dry in air. Ascitic fluid was spun at 300 g, suspended in potassium
chloride (KCl) and then fixed as above before slide making.
Slides were artificially aged by baking at 65°C for 2–4 h prior to
use to facilitate short turnaround times. Otherwise 1 week storage
at 4°C gave equally good results. All slides could be stored in a
4°C refrigerator for up to 6 weeks, or for longer at –40°C with a
desiccant if required.
FISH methods
The probes for all experiments were labelled by nick-translation
with biotin-11-dATP (BRL Bio-nick kit) or else with digoxygenin-
11-dUTP (Boehringer, Mannheim, Germany) according to the
suppliers’ instructions. The probes were purified through a
Sephadex G50 column and precipitated with salmon sperm DNA
and Escherichia coli tRNA.
Hybridization and detection were performed according to our
modification of the technique described by Pinkel et al in 1986
(Taylor et al, 1994).42 CPF Taylor et al
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Each of the four probes used was hybridized onto a separate
slide. If two types of preparation were available for an individual
patient then all four probes were hybridised to both sets of slides.
The neuroblastoma cells in these preparations were frequently
single, but often there was nuclear clumping. Clumped nuclei were
included in the study, but overlapping nuclei were excluded. On
some slides red blood corpuscles were still present, which take up
fluoroscein isothiocyanate (FITC) non-specifically, so that when
they were overlapping a tumour cell that cell had to be excluded.
The signals counted in each nucleus were of equal intensity to 
each other, though there was slight variation from cell to cell.
Minor hybridization spots and background fluorescence were
discounted. Signals had to be completely separate from 
one another to be included; paired spots close together were
counted as one signal.
Inevitably there was an admixture of tumour cells and normal
stromal or haemopoietic cells on each slide, which varied from one
area to another. It was meaningless, therefore, to include a pre-set
number of random nuclei and calculate average signal numbers.
Only the cells which were considered most likely to be tumour
cells, after parallel morphological examination of a May–
Grunwald–Giemsa (MGG) stained slide of the same preparation,
were included. In fact the proportion of non-tumour cells in the
tumour imprints was very low (< 15%) whereas in some bone
marrow smears it was considerably higher. However, there was no
difficulty in identifying which cells to include.
In all samples there were nuclei which did not react with the
DNA probes and also there were infrequent cells with three or
more signals. Control experiments were carried out with both
centromere probes, CT4-1 and pNb-9 using HFF nuclei and the
PCF cell line, examining 600 nuclei for signal number. In the
tumour imprints and bone marrow smears at least 50, and prefer-
ably 100, nuclei were examined which were believed to be of
tumour origin. The hybridization was repeated using more probe
DNA in those where < 70% of nuclei showed a consistent result. In
practice a small proportion of the cases reported below required a
repeat hybridisation for CT4-1 in order to achieve this result.
(See below for results of control experiments.)
The inclusion of the chromosome 8 centromere probe meant
that those cases with three or four copies of chromosome 1 could
be more securely classified as triploid or tetraploid rather than
merely trisomic or tetrasomic for chromosome 1. Chromosome 8
was selected from a panel of possible centromere probes because it
is not specifically duplicated or deleted in neuroblastoma, and
because the probe available is reliable and specific.
RESULTS
Control experiments using FISH were carried out on normal HFF
cells and neuroblastoma cell lines. The presence of del(1p), MYCN
amplification and tumour cell ploidy level were determined by the
application of FISH to various preparations of neuroblastoma
samples, mainly tumour imprints. Where feasible genetic data
were also obtained by Southern blotting (MYCN) and conventional
karyotyping.
Control experiments on normal HFF nuclei and
neuroblastoma cell lines
The sensitivity of the chosen probes was assessed by applying
them to preparations of normal HFF nuclei and examining 600
nuclei. Imprints of comparable normal tissue, or bone marrow
smears containing chromosomally normal but morphologically
identifiable non-haemopoietic cells were not readily available for
comparison. Ten neuroblastoma cell lines were evaluated by
karyotyping and chromosome painting in order to select those
most apposite as controls (Taylor et al, unpublished data).
Centromeres
The chromosome 1 centromere probe, pUC1.77, produced two
clear separate signals in 78% of normal nuclei. In addition, 2%
showed no signal, 14% showed one signal, 3% three signals and
3% four signals. The second centromere probe, p4.4 (chromosome
8 centromere), which was selected both as a control and to help
make an estimate of tumour cell ploidy, produced two signals in
83% of normal nuclei. Proportions for no signal, one, three and
four signals were 0%, 10%, 2% and 5% respectively.
Probe for del(1p)
Using the distal 1p probe, CT4-1, 80% of normal HFF nuclei
displayed two hybridization signals, < 1% no signal, 5% one
signal, 4% three signals, 9% four signals and 2% > 4 signals.
CT4-1 was also hybridized onto interphase preparations of the
neuroblastoma cell line PCF. Two signals were clearly visible in
approximately 80% of nuclei. This was the expected result
because this line has four copies of chromosome 1, two of which
have distal 1p deletions, leaving two intact copies to which the
terminal 1p probe will hybridize.
MYCN amplification
Using the MYCN probe pNb-9, two discrete signals were seen in
84% of HFF nuclei. In addition nuclei from four neuroblastoma
cell lines known to have amplification of MYCN were prepared.
IMR32 has approximately 20 copies of MYCN per cell, GOTO has
60 copies, SK-N-BE has 150 copies and Kelly 120 copies per cell.
This produces a very characteristic appearance under the fluores-
cence microscope which differs from background fluorescence.
Signal numbers in interphase nuclei were then counted in broad
categories: 0–20; 20–50; 50–100 and > 100. A median value was
therefore taken in each case. Wide cell to cell variation in copy
number was observed in the primary tumours with MYCN
amplification probably due to random segregation of DMs 
during mitosis.
In order to obtain an estimate of the number of copies in the
patient samples, signals were counted as accurately as possible at
microscopy in 100 nuclei and then divided into categories as above
depending on the number of MYCN signals seen. A median MYCN
content for each tumour sample was then taken. Frequently two or
three discrete signals from the MYCN probe were seen in the
nuclei of the cases in which the gene was not amplified.
Results on patient samples using FISH
Results were analysed on a total of 68 samples, which were
performed on a total of 58 patients. Six of the ten patients for
whom more than one sample was tested had both direct nuclear
preparations and tumour imprints available from the same biopsy,
and a further one had tumour imprints and bone marrow slides
from biopsies taken at the same time. Two had pre- and post-
chemotherapy samples (one bone marrow and one imprints) and
one had a bone marrow at the time of presentation and again at
relapse.FISH in neuroblastoma 43
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Of the 68 experiments 52 gave a full set of FISH results (75%).
A further five samples were only interpretable for MYCN, thus
producing a total of 56 experiments (82%) which yielded
clinically important prognostic information.
The majority of experiments (63%) were performed on tumour
imprints which gave an 81% success rate, while experiments on
marrow smears (10% of the total) and direct preparations (also
10%) were 100% successful. Cultured cells were used for five
patients (7%) and all yielded a full set of results. However, all
cultured cells were normal diploid with no MYCN amplification. It
is likely that only normal fibroblasts were present in the culture, a
fact borne out by the frequency of the same problem with conven-
tional cytogenetic techniques. A fine-needle aspiration (FNA), a
cytospin and an imprint from previously frozen tissue were found
to be unsuitable for FISH. The FNA had too few cells for a mean-
ingful assessment to be made; the cytospin produced overcrowded
cells with indistinct borders so that it was unclear which signals
arose from which cell; and the previously frozen tissue was full of
necrotic debris and the signals were very few and faint. Further
attempts to obtain results with these three types of preparation
were not made as the problems encountered were very likely to be
recurrent.
If the three unsuitable preparations, and the five cultured
samples are subtracted from the total number of experiments
performed, this leaves a total of 60 experiments in which one
could reasonably expect to obtain interpretable, meaningful
results. Of these 51 (85%) gave results. These 60 experiments
were carried out on 50 different patients (there were ten patients
who had two samples, as described above). A full set of FISH
results was obtained on 38 of the 50 patients (76%) and full or
partial results on 42 (84%).
The findings in these 38 patients were as follows: diploid
without MYCN amplification or del(1p) – ten patients (26%);
triploidy without MYCN amplification or del(1p) – 13 patients
(34%); Del(1p) without MYCN amplification, diploid – four
patients (11%); MYCN amplification and del(1p), diploid – six
patients (16%); Other findings, e.g. complex karyotypes with
out del(1p) or MYCN amplification – five patients (13%). A series
of photographs showing the results of a selection of the FISH
experiments on the above patients are presented in Figures 1–4.
Figure 1 (A) Chromosome 1 centromere; (B) CT4-1 (distal 1p probe); (C) MYCN probe; (D) chromosome 8 centromere. Typical appearance of the four
selected probes on a tumour imprint slide of average quality (case 5). There is debris on the slide which sometimes picks up fluorescence, and the chromosome
1 centromere probe occasionally gives a slightly diffuse signal, but interpretation of the signals is not affected. There are two copies of chromosome
1 centromere and CT4-1 and three copies of chromosome 8 centromere. MYCN is not amplified
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Correlations of FISH results with results from standard
techniques
Southern blotting
Biopsy samples were sent at presentation for Southern blotting in
32 (55%) of the the total of 58 patients in the study. The number of
individual patients (as opposed to the total sample number) is used
here because duplicate bone marrow samples were not used for
Southern blot techniques, and follow-up samples were not
requested. Blotting results were obtained on 27 of 32 samples
(84%), with the five failures being due to insufficient or poor
quality DNA from small samples.
There are 22 patients on whom there are both FISH results and
Southern blot results for MYCN, and of these there is correlation of
findings in 21 (95%). The one discrepancy is on a sample early in
the study in which FISH results were misinterpreted as positive for
MYCN, but the Southern blot was negative.
Conventional karyotyping
There were 62 different samples on which karyotyping was a
possibility, as the total of 68 samples included six cases where
direct cell suspension and imprint were made from the same
biopsy. Karyotyping was attempted on 30 (48%) of the 62
samples, and failed in five (17%), while a further 12 (40%) were
only successful in long-term culture where both phase microscopy
and the consistently normal results indicated that only fibro
blasts remained in the culture. One sample was sent but not
processed, and one was inadequate. Full or partial karyotyping
results  were obtained in 11 (37%) of the 30 attempted. In three
cases only an estimate of ploidy and account of the approximate
number of marker chromosomes were possible because of poor
qualitychromosomes. In a further three cases two copies of
chromosome 1 could be identified, although a complex
hyperdiploid karyotype meant that the presence of further
abnormal copies of chromosome 1 could not be excluded. 
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Figure 2 (A) Chromosome 1 centromere; (B) CT4-1 (distal 1p probe); (C) MYCN probe; (D) chromosome 8 centromere. Bone marrow smear showing two
populations of cells (case 29). Twenty-five per cent are probably tetraploid cells and the rest are diploid (centromere probes 1 and 8). The large cells show a
maximum of three copies of CT4-1 while the diploid cells have two copies, suggesting that there is a 1p deletion in the tetraploid population but not the diploid
population. MYCN is not amplified, with single copies of this small probe being visible in some cellsFISH in neuroblastoma 45
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This leaves five samples (17% of those attempted) for which a 
full karyotype was obtained. Two of these were from the same
patient but were different samples (one tumour biopsy and one
bone marrow) taken at the same time and producing duplicate
results.
Ten of the eleven cases with karyotyping results also had
results using FISH. (The exception was case 12 on whom only
frozen tissue had been available for FISH.) The 10 cases with
both karyotyping results and FISH results showed a full
correlation of results in all cases. In four patients a full karyotype
was available (one bone marrow aspirate and three solid tumour
biopsies), and of these one had a del(1p) and the remaining 
three did not, which correlated fully with FISH results. In three of
the six samples in which there were incomplete karyo
typing results, complex rearrangements were detected by both
methods, but del(1p) was detected by FISH in some cell popula-
tions, while karyotyping was limited to visualisation of marker
chromosomes.
DISCUSSION
The aim of this work was to develop simple, rapid and readily
reproducible tests, for the presence of the clinically significant
genetic aberrations found in neuroblastoma. This technique
produces reliable clinically relevant results on a small tissue
sample and may have a role in a national laboratory in which data
on all neuroblastomas can be collated. It is the intention of the
ENSG to cooperate with such national laboratories in various
European countries.
Overall this study found 26% of neuroblastomas were diploid
without amplification of MYCN or del(1p); 34% were apparently
triploid without MYCN amplification or del(1p); 11% were diploid
with del(1p) but without MYCN amplification and 16% had both
MYCN amplification and del(1p). A further 13% had other
changes but without del(1p) or MYCN amplification.
The incidence of MYCN amplification in primary neuroblas-
toma has been quoted as around 38% in stage 3 and 4 tumours, and
Figure 3 (A) Chromosome 1 centromere; (B) CT4-1 (distal 1p probe); (C) MYCN probe; (D) chromosome 8 centromere. Imprint of a patient’s tumour with
del(1p) and MYCN amplification (case 52). This imprint is very crowded with tumour cells and debris, a common finding, but the results are still perfectly clear.
There are two copies of both centromere probes so the cells are likely to be diploid. The distal 1p probe CT4-1 is present in only one copy per cell, providing
definite evidence of a 1p36 deletion, and MYCN is clearly amplified with over 100 signals per cell
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5–10% in stages 1,2 and 4S (Brodeur et al, 1984; Brodeur and
Fong, 1989). Our finding of 16% is in keeping with results in other
studies: 17% of 12 tumours (Shapiro et al, 1993), 15% of 59
tumours (Bourhis et al, 1991a) and 25% of 147 tumours (Look et
al, 1991). In a series of 316 consecutive cases from the French
NBL 90 study, MYCN amplification was detected by Southern
blotting in 10% of 225 children tested (Rubie et al, 1997).
Similarly our finding of 34% apparently triploid cases is in keeping
with Bourhis et al (1991) (47%) and Oppedal et al (1988) (34%).
Molecular techniques detect chromosome 1p deletion in
30–40% of tumours (Fong et al, 1992; Takayama et al, 1992;
Caron et al, 1993; Schleiermacher et al, 1994), although there are
lower estimates, of 20% (Takeda et al, 1994) and 27% (Peter et et
al, 1992). Rubie et al (1997) found an incidence of LOH1p of 10%
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Figure 4 (A) Chromosome 1 cent.-imprint; (B) Chromosome 1 cent.-direct preparation; (C) chromosome 8 cent.-imprint; (D) Chromosome 8 cent.-direct
preparation; (E) CT4-1-direct preparation; (F) MYCN-imprint. Photographs showing the difference between a tumour imprint and a direct nuclear preparation
(case 24). The direct preparation is much cleaner with no red cells or other debris on the slide. Both sets of results show three copies of each probe, implying
triploidy, with no MYCN amplificationFISH in neuroblastoma 47
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in 91 cases attempted. In this study the incidence of del(1p) was
26% and the incidence of MYCN amplification was 16%. The
cases with MYCN amplification were a subset (60%) of those with
del(1p). Comparable findings have been reported in other series, in
that all cases with MYCN amplification also had 1p deletion, while
conversely approximately 60% of cases with 1p deletion also have
MYCN amplification (Fong et al, 1989; Caron et al, 1993).
In this study results of prognostic significance were obtained in
84% of cases, and a full set of results on all four probes in 76%.
There was 100% success using direct preparations. Probes were
hybridized onto separate slides with no attempt at double
hybridization onto single slides, to avoid the cumulative failure
rate of multiple hybridization experiments. Published data show a
much lower success rate when performing FISH with more than
one probe. In one study a two-probe experiment on direct prepara-
tions and cultures produced a double hybridization success rate of
38.5% (Christiansen et al, 1992).
Controls for FISH
HFFs and neuroblastoma cell lines were used as negative and posi-
tive controls. The signals in 600 nuclei were counted for each of
the probes in the study. The least efficient probe on the HFF prepa-
rations was the chromosome 1 centromere, pUC1.77. This showed
two discrete signals in 78% of nuclei, no signal in 2%, one signal
in 14%, three signals in 3% and four signals in 3%. A similar
figure (75.8%) is given for control experiments with the same
probe in another study (Christiansen et al, 1992). It was decided
that concordance of signal number in at least 70% of nuclei
(whether on imprints or cultured cells) was required to be able to
state the number of copies present reliably. Conversely, sub-popu-
lations with different copy numbers needed to comprise at least
30% of the cell population, so a biclonal tumour needed to have
two populations each over 30% of the total. This stipulation may
have meant that minor sub-clones were not recorded, but this is
unlikely to be a consideration of clinical importance as the genetic
aberrations of prognostic significance are very consistent.
Detection of MYCN
Results were obtained using FISH with the MYCN probe in 84% of
cases. Samples were sent for Southern blotting in 55% of patients
in the study, and results were obtained in 47% of patients. A
similar proportion (49%) were sent for blotting in a much larger
series of 298 patients, with results being obtained in almost all of
these (48%) (Look et al, 1991). However no alternative method of
MYCN copy number estimation was being studied. A study
comparing FISH results for MYCN in neuroblastoma cell lines
with Southern blotting results found full correlation, with 13 of the
20 cell lines showing amplification of MYCN with both FISH and
blotting (Shapiro et al, 1993). However no blotting results were
available for any of the 12 primary tumour samples evaluated, of
which two (17%) were found to have MYCN amplification using
FISH.
In our study ten neuroblastoma cell lines were evaluated with
FISH of which four had known amplification of MYCN. There was
full correlation of FISH estimates of MYCN copy number with
available cell line data. In our study both Southern blotting and
FISH results were available in 22 patients. Of these 18 were nega-
tive for MYCN amplification both with FISH and blotting. Four
had amplification of MYCN using FISH and three had 
amplification on Southern blotting. In these three the copy number
estimate from blotting was consistently lower than that from FISH,
which may be because of admixture of the tumour with normal
stromal tissue (Shapiro et al, 1993). In the discrepant case the
appearance of the amplification was not typical, in that there was
intercellular uniformity of MYCN copy number. This case
appeared early in the series and with experience the unusually
coarse, bright background fluorescence would not have been inter-
preted as MYCN amplification.
The correlation between FISH and Southern blotting in this
study is therefore reduced to 95%, which still compares well with
other reports. A similar study using FISH and Southern blotting to
detect ERBB2 amplification in primary breast tumours detected
amplification in ten of 44 tumours using interphase FISH, but in
only eight using a slot blot technique (Kallioniemi et al, 1992). In
a study of 23 neuroblastomas which were all carrying MYCN
amplification by Southern blotting, a 96% correlation was found
with PCR (Crabbe et al, 1992). A more recent report comparing
the FISH with semi-quantitative PCR for detection of MYCN
amplification in neuroblastoma cell lines found that FISH could
detect one cell in 1000 normal cells, whilst PCR required 10%
tumour cells to reliably detect the amplification (Eckschlager and
McClain, 1996)
Ploidy
The detection of ploidy in this study has been based on the assess-
ment of two centromere probes, plus, in cases without MYCN
amplification, a count of the number of copies of the MYCN probe
in its normal position on chromosome 2. This method provides an
adequate guide to ploidy level in the majority of cases. For
absolute certainty of ploidy in any sample one would need to count
centromere signals from the majority of chromosomes. This issue
has not been addressed much in the literature; one paper states that
‘usually three or more chromosome specific probes have to be
used to estimate the ploidy of a tissue by NISH on interphase
nuclei’ (Stock et al, 1993). On this basis the three chromosomes
assessed in this study would be regarded as sufficient.
CONCLUSION
This study has shown the utility of fluorescence in situ hybridiza-
tion in the detection of MYCN amplification, ploidy and 1p dele-
tions in tumour imprints, bone marrow smears and direct nuclear
preparations from neuroblastomas. The pilot study (Taylor et al,
1994) was among the first to describe the use of these types of
preparation for FISH and was also the first publication describing
visualisation of these three clinically significant genetic prognostic
factors in neuroblastoma. This new study is now the largest series
of patients in whom FISH has been used in this way. Other studies
have evaluated only one of the clinically important genetic aberra-
tions. One series reports on 20 patients in whom MYCN amplifica-
tion was assessed by FISH and by Southern blotting together with
karyotyping. Concordant results were obtained in the 14 fully
evaluable patients (Avet-Loiseau et al, 1995). Another study
successfully evaluated 1p deletion by FISH and RFLP analysis in
8/9 neuroblastoma cell lines and 23/28 patient samples (Combaret
et al, 1995). Both authors felt that FISH offered many advantages
over conventional molecular approaches. A series of 54 stage 1, 2
and 4S patients has been studied using FISH, cytogenetics,
Southern blotting and PCR to detect del(1p), MYCN amplificationand ploidy (Ambros et al, 1995). However, the low level of posi-
tive results in these patients and the absence of any control data
makes this report difficult to interpret.
The importance of various biological factors as markers of
aggressiveness of the disease has been recognized for some time,
and measurement of these variables has increasingly been carried
out in the clinical trial setting. The agreed goal of the International
Neuroblastoma Staging System and Response Criteria Committee
is to collect information on tumour histology, ploidy, MYCN gene
copy number, chromosome 1p deletion and serum concentrations
of neurone specific enolase, ferritin and lactate dehydrogenase for
all neuroblastomas (Brodeur et al, 1993; Castleberry et al, 1997).
Analysis of these data will indicate which biological features are
sufficiently discriminatory to form the basis of therapeutic deci-
sions. Results of the investigations into MYCN amplification,
ploidy and 1p deletion need to be available at the time of diagnosis
and commencement of treatment. The chosen methodology needs
to produce reliable, rapid and reproducible results. Other methods
of evaluating these biological factors require more tissue than is
frequently obtained, plus expensive or specialized techniques that
are not readily available in all centres. Our fast FISH method has
now been thoroughly evaluated. It is able to produce reliable
results in a much higher proportion of patients (84%) than conven-
tional methods. It is therefore appropriate that this application of
FISH should become accessible to all clinicians practising in this
field. The technique is simple, and, unlike complex cytogenetic
and molecular biological studies, could be performed rapidly
either in a national reference centre or in routine service
laboratories without the need for complex and expensive comput-
erised imaging techniques.
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